Adrián Mosquera Orgueira, MD, PhD,

Adrián Mosquera Orgueira, MD, PhD, is a specialist in Hematology and Hemotherapy and lead researcher of the Computational and Genomic Hematology Group at the Health Research Institute of Santiago de Compostela.

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 29th 2025

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Adrián Mosquera Orgueira, MD, PhD,

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

Latest Updated Articles

Trending on OncLive

Sacituzumab Govitecan Approved in Europe for First-Line PD-L1 Inhibitor–Ineligible TNBC

Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC

Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia

NCCN Includes PCR ctDNA-MRD Testing in MIBC Treatment Algorithm

Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability